Literature DB >> 14732829

Clinical caveats on medical assessment and treatment of pain after TBI.

Cindy B Ivanhoe1, Eric T Hartman.   

Abstract

The diagnosis and management of pain in the patient with traumatic brain injury (TBI) can be difficult in light of the limitations imposed by the cognitive, language, and behavioral deficits. With patients in the acute rehabilitation setting, one must be vigilant for the often subtle signs and symptoms of pain. Causes more commonly seen in the population with TBI as a consequence of the injury itself include dysautonomia, neuropathic pain, spasticity, and heterotopic ossification. Headaches may be a consequence of TBI or associated with it for other reasons. Sources of pain associated with TBI include deep venous thrombosis and others. The reader is reminded that patients with TBI are subject to all the causes of pain that affect the general population.

Entities:  

Mesh:

Year:  2004        PMID: 14732829     DOI: 10.1097/00001199-200401000-00004

Source DB:  PubMed          Journal:  J Head Trauma Rehabil        ISSN: 0885-9701            Impact factor:   2.710


  3 in total

1.  Sustained blockade of neurotrophin receptors TrkA, TrkB and TrkC reduces non-malignant skeletal pain but not the maintenance of sensory and sympathetic nerve fibers.

Authors:  Joseph R Ghilardi; Katie T Freeman; Juan M Jimenez-Andrade; William G Mantyh; Aaron P Bloom; Karyn S Bouhana; David Trollinger; James Winkler; Patrice Lee; Steven W Andrews; Michael A Kuskowski; Patrick W Mantyh
Journal:  Bone       Date:  2010-09-18       Impact factor: 4.398

2.  Chronic post-traumatic headache: clinical findings and possible mechanisms.

Authors:  Ruth Defrin
Journal:  J Man Manip Ther       Date:  2014-02

3.  Administration of a tropomyosin receptor kinase inhibitor attenuates sarcoma-induced nerve sprouting, neuroma formation and bone cancer pain.

Authors:  Joseph R Ghilardi; Katie T Freeman; Juan M Jimenez-Andrade; William G Mantyh; Aaron P Bloom; Michael A Kuskowski; Patrick W Mantyh
Journal:  Mol Pain       Date:  2010-12-07       Impact factor: 3.395

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.